Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Arcutis Biotherapeutics, Inc. (ARQT : NSDQ)
 
 • Company Description   
Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.

Number of Employees: 342

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.76 Daily Weekly Monthly
20 Day Moving Average: 1,920,112 shares
Shares Outstanding: 119.20 (millions)
Market Capitalization: $1,640.22 (millions)
Beta: 1.77
52 Week High: $17.75
52 Week Low: $7.86
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.69% -0.58%
12 Week -5.56% -17.25%
Year To Date -1.22% -6.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3027 TOWNSGATE ROAD SUITE 300
-
WESTLAKE VILLAGE,CA 91361
USA
ph: 805-418-5006
fax: -
ir@arcutis.com http://www.arcutis.com
 
 • General Corporate Information   
Officers
Todd Franklin Watanabe - President; Chief Executive Officer and Director
Keith R. Leonard - Director; Chairman
David Topper - Chief Financial Officer
Bhaskar Chaudhuri - Director
Terrie Curran - Director

Peer Information
Arcutis Biotherapeutics, Inc. (CORR.)
Arcutis Biotherapeutics, Inc. (RSPI)
Arcutis Biotherapeutics, Inc. (CGXP)
Arcutis Biotherapeutics, Inc. (BGEN)
Arcutis Biotherapeutics, Inc. (GTBP)
Arcutis Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03969K108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 119.20
Most Recent Split Date: (:1)
Beta: 1.77
Market Capitalization: $1,640.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.57 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 11.50
Price/Cash Flow: -
Price / Sales: 7.71
EPS Growth
vs. Year Ago Period: 37.50%
vs. Previous Quarter: -122.22%
Sales Growth
vs. Year Ago Period: 32.84%
vs. Previous Quarter: -7.73%
ROE
06/30/25 - -
03/31/25 - -80.66
12/31/24 - -77.20
ROA
06/30/25 - -
03/31/25 - -32.94
12/31/24 - -32.77
Current Ratio
06/30/25 - -
03/31/25 - 3.55
12/31/24 - 4.15
Quick Ratio
06/30/25 - -
03/31/25 - 3.37
12/31/24 - 3.97
Operating Margin
06/30/25 - -
03/31/25 - -60.95
12/31/24 - -71.25
Net Margin
06/30/25 - -
03/31/25 - -60.95
12/31/24 - -71.25
Pre-Tax Margin
06/30/25 - -
03/31/25 - -60.67
12/31/24 - -70.92
Book Value
06/30/25 - -
03/31/25 - 1.20
12/31/24 - 1.35
Inventory Turnover
06/30/25 - -
03/31/25 - 1.67
12/31/24 - 1.37
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.75
12/31/24 - 0.68
Debt-to-Capital
06/30/25 - -
03/31/25 - 43.00
12/31/24 - 40.49
 

Powered by Zacks Investment Research ©